A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Summary

A Phase 1B, multi-center, double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) clinical study is designed to evaluate ASLAN004 versus placebo in patients who have moderate-severe AD. The treatment period duration will be 8 weeks with a 12-week follow-up period after the end of treatment.

Timeline

Start

2019-09-09

Primary completion

2021-10-28

Completion

2021-12-03

Publications

• Cevikbas F, Ward A, Veverka KA. Eblasakimab, an Anti-IL-13Ralpha1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate-to-Severe Atopic Dermatitis. BioDrugs. 2024 Nov;38(6):821-830. doi: 10.1007/s40259-024-00685-y. Epub 2024 Oct 15.

Drugs

Indications